Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | ELANE | P08246 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020552 | 0.86 | DDAH1 (0.71) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL423424 | 0.83 | DDAH1 (0.67) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29751905 | 0.83 | DDAH1 (0.67) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27869881 | 0.82 | DDAH1 (0.53) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11345934 | 0.82 | DDAH1 (0.65) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5623032 | 0.81 | DDAH1 (0.65) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL15195141 | 0.81 | SMN1; SMN2 (0.62) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL18013088 | 0.81 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11779882 | 0.80 | DDAH1 (0.63) | DDAH1ADRA2CALDH1A1KMT2AMEN1 | |
| SCHEMBL9531515 | 0.79 | DDAH1 (0.71) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2021-07-29 | — | — | US | disclosed |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2019-07-11 | — | — | US | disclosed |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | ABEL-SANTOS ERNESTO (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016127102-A2 | INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS | ABEL-SANTOS ERNESTO (US) | 2016-08-11 | — | — | WO | disclosed |
| US-9303026-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20140179709-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-06-26 | — | — | US | disclosed |
| US-8624025-B2 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-01-07 | — | — | US | disclosed |
| US-8513295-B2 | Viral and fungal inhibitors | GEORGETOWN UNIVERSITY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090030000-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2009-01-29 | — | — | US | disclosed |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2007-06-28 | — | — | US | disclosed |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | DE KOCK HERMAN A | 2007-05-31 | — | — | US | disclosed |
| EP-1670773-B1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARM LTD (IE) | 2007-02-07 | — | — | EP | disclosed |
| US-7166604-B2 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-01-23 | — | — | US | disclosed |
| EP-1353911-A4 | ANTIVIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| EP-1353911-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002050045-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149530-A1 | For treatment of picornavirus infections in mammals | HAVCR2, EIF2AK2, MAVS | DDAH1 3139/4885ADRA2C 4193/4885ALDH1A1 2053/4885 |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | CASP3, SI, PYCARD | DDAH1 2270/4885ADRA2C 4119/4885ALDH1A1 4772/4885 |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | STS, MPST, SULT1E1 | DDAH1 532/4885ADRA2C 4519/4885ALDH1A1 858/4885 |
| US-20090030000-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | DDAH1 1778/4885ADRA2C 4525/4885ALDH1A1 2469/4885 |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | DDAH1 2270/4885ADRA2C 4119/4885ALDH1A1 4772/4885 |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | DDAH1 2270/4885ADRA2C 4119/4885ALDH1A1 4772/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | DDAH1 3763/4885ADRA2C 4438/4885ALDH1A1 4673/4885 |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | DDAH1 2270/4885ADRA2C 4119/4885ALDH1A1 4772/4885 |
| US-20070149531-A1 | such as 7-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-4-ethoxy-cinnoline, used in the treatment of picornavirus infections in humans | EIF2AK2, IFNAR1, HAVCR2 | DDAH1 2482/4885ADRA2C 2435/4885ALDH1A1 859/4885 |
| US-20140179709-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | DDAH1 1778/4885ADRA2C 4525/4885ALDH1A1 2469/4885 |
| US-20040077633-A1 | N-Heterocyclic derivatives; picornavirus infections in mammals; human rhinovirus | RNASEH1, RPL35, SARS1 | DDAH1 1019/4885ADRA2C 3726/4885ALDH1A1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.